New data reveals that retatrutide, a dual-action medication, might represent a significant improvement in body management. This therapy combines the properties of a GLP-1 receptor and a GIP analog, possibly offering a more outcome than current therapies . Patient research have revealed encouraging results , including substantial decreases in weigh